CAMRF (Camurus AB) Piotroski F-Score: 5 (As of Jun. 24, 2026) — Near Median


CAMRF Camurus AB CAMRF
79 GF Score
Price $54.00
GF Value $83.14
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB Piotroski F-Score?

Camurus AB CAMRF -3.57% 79 Piotroski F-Score is 5 as of Jun. 24, 2026, which is at its 10-year median of 5.00. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,341 Biotechnology companies, Camurus AB ranks better than 85.09% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Camurus AB has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Camurus AB's Piotroski F-Score or its related term are showing as below:

CAMRF' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 5   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of Camurus AB was 9. The lowest was 1. And the median was 5.

Camurus AB  (OTCPK:CAMRF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Camurus AB Piotroski F-Score Related Terms


Camurus AB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Camurus AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB Piotroski F-Score Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 8.00 9.00 5.00 5.00

Camurus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 5.00 5.00 5.00

CAMRF vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Camurus AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Camurus AB Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Camurus AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Camurus AB's Piotroski F-Score falls into.


CAMRF
79GF Score
Camurus AB CAMRF
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 25.637 + 20.554 + 10.855 + 15.436 = $72.5 Mil.
Cash Flow from Operations was 39.356 + 17.12 + 27.485 + 17.406 = $101.4 Mil.
Revenue was 70.746 + 60.503 + 49.977 + 57.217 = $238.4 Mil.
Gross Profit was 66.438 + 56.306 + 46.063 + 53.228 = $222.0 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(391.711 + 463.34 + 493.664 + 510.031 + 532.148) / 5 = $478.1788 Mil.
Total Assets at the begining of this year (Mar25) was $391.7 Mil.
Long-Term Debt & Capital Lease Obligation was $9.5 Mil.
Total Current Assets was $495.3 Mil.
Total Current Liabilities was $42.8 Mil.
Net Income was 7.075 + 12.645 + 13.38 + 19.467 = $52.6 Mil.

Revenue was 42.421 + 46.886 + 50.353 + 55.102 = $194.8 Mil.
Gross Profit was 39.388 + 43.61 + 47.32 + 51.225 = $181.5 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(293.983 + 327.269 + 348.663 + 342.013 + 391.711) / 5 = $340.7278 Mil.
Total Assets at the begining of last year (Mar24) was $294.0 Mil.
Long-Term Debt & Capital Lease Obligation was $8.6 Mil.
Total Current Assets was $362.9 Mil.
Total Current Liabilities was $38.4 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Camurus AB's current Net Income (TTM) was 72.5. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Camurus AB's current Cash Flow from Operations (TTM) was 101.4. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=72.482/391.711
=0.18503948

ROA (Last Year)=Net Income/Total Assets (Mar24)
=52.567/293.983
=0.17880966

Camurus AB's return on assets of this year was 0.18503948. Camurus AB's return on assets of last year was 0.17880966. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Camurus AB's current Net Income (TTM) was 72.5. Camurus AB's current Cash Flow from Operations (TTM) was 101.4. ==> 101.4 > 72.5 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=9.514/478.1788
=0.01989632

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=8.635/340.7278
=0.02534281

Camurus AB's gearing of this year was 0.01989632. Camurus AB's gearing of last year was 0.02534281. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=495.334/42.811
=11.57025064

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=362.94/38.408
=9.44959383

Camurus AB's current ratio of this year was 11.57025064. Camurus AB's current ratio of last year was 9.44959383. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Camurus AB's number of shares in issue this year was 59.829. Camurus AB's number of shares in issue last year was 59.682. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=222.035/238.443
=0.93118691

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=181.543/194.762
=0.93212742

Camurus AB's gross margin of this year was 0.93118691. Camurus AB's gross margin of last year was 0.93212742. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=238.443/391.711
=0.60872174

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=194.762/293.983
=0.66249409

Camurus AB's asset turnover of this year was 0.60872174. Camurus AB's asset turnover of last year was 0.66249409. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Camurus AB has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Camurus AB (CAMRF) has a Piotroski F-Score of 5 as of Jun. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Camurus AB and its competitors. This is near median its historical median of 5.00. Over the past decade, Camurus AB's Piotroski F-Score has ranged from 1.00 to 9.00. According to the industry distribution chart, Camurus AB ranks #200 out of 1341 companies in the Biotechnology industry, placing it in the top 14.9%.
Is Camurus AB's Piotroski F-Score too high?
Camurus AB's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 9.00. The Biotechnology industry median Piotroski F-Score is 3.00. Camurus AB's value of 5 is 66.7% above this industry median. Based on the distribution chart, Camurus AB ranks #200 out of 1341 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #200 out of 1341 companies for Piotroski F-Score. This places Camurus AB in the top 15% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Camurus AB's value of 5 is 66.7% above this benchmark. Historically, Camurus AB's own Piotroski F-Score has ranged from 1.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 3.00, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,341 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Piotroski F-Score of 5 is 66.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 66.7% above the Biotechnology industry median of 3.00. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Piotroski F-Score is 5 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14. GuruFocus considers Camurus AB to be Significantly Undervalued.

Key valuation signals for CAMRF:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
  • GF Score™: 79/100 with 1 warning sign
  • Industry Position: 66.7% above the Biotechnology median (#200 of 1341)

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score

Get the complete analysis for CAMRF

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.00
Price
$83.14
GF Value